|Mr. Manuel Llobet||Chief Exec. Officer and Exec. Director||407.96k||N/A||53|
|Mr. Nicolas Alexander Ulrich Wykeman||Fin. Director and Exec. Director||N/A||N/A||52|
|Ms. Beverly Lees||Operations Director||N/A||N/A||N/A|
|Dr. Murray Skinner||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Santiago Puig||Bus. Devel. Director||N/A||N/A||N/A|
Allergy Therapeutics plc, a specialty pharmaceutical company, focusing on allergy vaccination primarily in Europe. The companys primary flagship products consist of the Pollinex Quattro for the treatment of allergic conditions; and monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen. It offers sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; probiotic products, such as Kallergen-Th, ATI Prob, and Pollagen; Acarovac Plus, a novel tyrosine-adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzyl penicillin and related antibiotics (beta lactams) by means of cutaneous tests (prick and intradermal). It is also developing products based on synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen Th and SynGut; Polyvac, a peanut VLP adjuvanted specific immunotherapy; Acarovac Plus and Acarovac MPL that are next generation products for dust mite immunotherapy; and G102, G204, G205, and G306, as well as PQBirch 301 and PQBirch 204 that are subcutaneous immunotherapies, which are in various development phases. The company markets its products in injectable and sublingual formats under various brands. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.
Allergy Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.